Top

Published in:

01-10-2009 | Research Paper

Cancer cell lines release glutamate into the extracellular environment

Authors: Eric P. Seidlitz, Mohit K. Sharma, Zeina Saikali, Michelle Ghert, Gurmit Singh

Published in: Clinical & Experimental Metastasis | Issue 7/2009

Abstract

Bone is one of the most frequent sites for metastasis of breast and prostate cancers. Bone metastases are associated with pathologic changes in bone turnover and severe pain. The mechanisms that trigger these effects are not well understood, but it is postulated that tumour cells release factors which interfere with signalling processes critical to bone homeostasis. We have identified that several cancer cell lines known to cause bone disruption in animal models of bone metastasis appear to secrete glutamate into their extracellular environment in vitro. Although these cells also express specific glutamate receptors, the implications of this potentially disruptive chemical signal are discussed in relation to normal glutamate-dependent communication processes in bone and a possible mechanistic connection is made between tumour cell glutamate release and the development of pathological changes in bone turnover.

Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(8, Suppl):1588–1594. doi:10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G CrossRefPubMed

Orr FW, Lee J, Duivenvoorden WC, Singh G (2000) Pathophysiologic interactions in skeletal metastasis. Cancer 88(12, Suppl):2912–2918. doi:10.1002/1097-0142(20000615)88:12+<2912::AID-CNCR6>3.0.CO;2-8 CrossRefPubMed

Vukmirovic-Popovic S, Colterjohn N, Lhotak S, Duivenvoorden WC, Orr FW, Singh G (2002) Morphological, histomorphometric, and microstructural alterations in human bone metastasis from breast carcinoma. Bone 31(4):529–535. doi:10.1016/S8756-3282(02)00847-5 CrossRefPubMed

Rose AA, Siegel PM (2006) Breast cancer-derived factors facilitate osteolytic bone metastasis. Bull Cancer 93(9):931–943PubMed

Bonfil RD, Chinni S, Fridman R, Kim HR, Cher ML (2007) Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis. Urol Oncol 25(5):407–411. doi:10.1016/j.urolonc.2007.05.008 PubMed

Skerry TM (2008) The role of glutamate in the regulation of bone mass and architecture. J Musculoskelet Neuronal Interact 8(2):166–173PubMed

Bussard KM, Gay CV, Mastro AM (2008) The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 27(1):41–55. doi:10.1007/s10555-007-9109-4 CrossRefPubMed

Chenu C (2002) Glutamatergic regulation of bone remodeling. J Musculoskelet Neuronal Interact 2(3):282–284PubMed

Hinoi E, Takarada T, Yoneda Y (2004) Glutamate signaling system in bone. J Pharmacol Sci 94(3):215–220. doi:10.1254/jphs.94.215 CrossRefPubMed

10.

Esquenazi S, Monnerie H, Kaplan P, Le Roux P (2002) BMP-7 and excess glutamate: opposing effects on dendrite growth from cerebral cortical neurons in vitro. Exp Neurol 176(1):41–54. doi:10.1006/exnr.2002.7906 CrossRefPubMed

11.

Li T, Ghishan FK, Bai L (2005) Molecular physiology of vesicular glutamate transporters in the digestive system. World J Gastroenterol 11(12):1731–1736PubMed

12.

Skerry TM, Genever PG (2001) Glutamate signalling in non-neuronal tissues. Trends Pharmacol Sci 22(4):174–181. doi:10.1016/S0165-6147(00)01642-4 CrossRefPubMed

13.

Hinoi E, Takarada T, Ueshima T, Tsuchihashi Y, Yoneda Y (2004) Glutamate signaling in peripheral tissues. Eur J Biochem 271(1):1–13. doi:10.1046/j.1432-1033.2003.03907.x CrossRefPubMed

14.

Serre CM, Farlay D, Delmas PD, Chenu C (1999) Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers. Bone 25(6):623–629. doi:10.1016/S8756-3282(99)00215-X CrossRefPubMed

15.

Chenu C (2002) Glutamatergic regulation of bone resorption. J Musculoskelet Neuronal Interact 2(5):423–431PubMed

16.

Chenu C (2002) Glutamatergic innervation in bone. Microsc Res Tech 58(2):70–76. doi:10.1002/jemt.10120 CrossRefPubMed

17.

Spencer GJ, Genever PG (2003) Long-term potentiation in bone—a role for glutamate in strain-induced cellular memory? BMC Cell Biol 4:9. doi:10.1186/1471-2121-4-9 CrossRefPubMed

18.

Szczesniak AM, Gilbert RW, Mukhida M, Anderson GI (2005) Mechanical loading modulates glutamate receptor subunit expression in bone. Bone 37(1):63–73. doi:10.1016/j.bone.2003.10.016 CrossRefPubMed

19.

Takarada T, Yoneda Y (2008) Pharmacological topics of bone metabolism: glutamate as a signal mediator in bone. J Pharmacol Sci 106(4):536–541. doi:10.1254/jphs.FM0070243 CrossRefPubMed

20.

Patton AJ, Genever PG, Birch MA, Suva LJ, Skerry TM (1998) Expression of an N-methyl-D-aspartate-type receptor by human and rat osteoblasts and osteoclasts suggests a novel glutamate signaling pathway in bone. Bone 22(6):645–649. doi:10.1016/S8756-3282(98)00061-1 CrossRefPubMed

21.

Chenu C, Serre CM, Raynal C, Burt-Pichat B, Delmas PD (1998) Glutamate receptors are expressed by bone cells and are involved in bone resorption. Bone 22(4):295–299. doi:10.1016/S8756-3282(97)00295-0 CrossRefPubMed

22.

Laketic-Ljubojevic I, Suva LJ, Maathuis FJ, Sanders D, Skerry TM (1999) Functional characterization of N-methyl-D-aspartic acid-gated channels in bone cells. Bone 25(6):631–637. doi:10.1016/S8756-3282(99)00224-0 CrossRefPubMed

23.

Gu Y, Genever PG, Skerry TM, Publicover SJ (2002) The NMDA type glutamate receptors expressed by primary rat osteoblasts have the same electrophysiological characteristics as neuronal receptors. Calcif Tissue Int 70(3):194–203. doi:10.1007/s00223-001-2004-z CrossRefPubMed

24.

Hinoi E, Fujimori S, Takemori A, Kurabayashi H, Nakamura Y, Yoneda Y (2002) Demonstration of expression of mRNA for particular AMPA and kainate receptor subunits in immature and mature cultured rat calvarial osteoblasts. Brain Res 943(1):112–116. doi:10.1016/S0006-8993(02)02726-9 CrossRefPubMed

25.

Mason DJ, Suva LJ, Genever PG, Patton AJ, Steuckle S, Hillam RA et al (1997) Mechanically regulated expression of a neural glutamate transporter in bone: a role for excitatory amino acids as osteotropic agents? Bone 20(3):199–205. doi:10.1016/S8756-3282(96)00386-9 CrossRefPubMed

26.

Stains JP, Civitelli R (2005) Cell-to-cell interactions in bone. Biochem Biophys Res Commun 328(3):721–727. doi:10.1016/j.bbrc.2004.11.078 CrossRefPubMed

27.

Kato S, Negishi K, Mawatari K, Kuo CH (1992) A mechanism for glutamate toxicity in the C6 glioma cells involving inhibition of cystine uptake leading to glutathione depletion. Neuroscience 48(4):903–914. doi:10.1016/0306-4522(92)90278-A CrossRefPubMed

28.

Ye ZC, Sontheimer H (1999) Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 59(17):4383–4391PubMed

29.

Kim JY, Kanai Y, Chairoungdua A, Cha SH, Matsuo H, Kim DK et al (2001) Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells. Biochim Biophys Acta 1512(2):335–344. doi:10.1016/S0005-2736(01)00338-8 CrossRefPubMed

30.

Sontheimer H (2003) Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage. Trends Neurosci 26(10):543–549. doi:10.1016/j.tins.2003.08.007 CrossRefPubMed

31.

Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY et al (2005) Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci 25(31):7101–7110. doi:10.1523/JNEUROSCI.5258-04.2005 CrossRefPubMed

32.

Duivenvoorden WC, Popovic SV, Lhotak S, Seidlitz E, Hirte HW, Tozer RG et al (2002) Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Cancer Res 62(6):1588–1591PubMed

33.

Duivenvoorden WC, Vukmirovic-Popovic S, Kalina M, Seidlitz E, Singh G (2007) Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer. Br J Cancer 96:1526–1531. doi:10.1038/sj.bjc.6603740 CrossRefPubMed

34.

Hinoi E, Fujimori S, Yoneda Y (2003) Modulation of cellular differentiation by N-methyl-D-aspartate receptors in osteoblasts. FASEB J 17(11):1532–1534PubMed

35.

Merle B, Itzstein C, Delmas PD, Chenu C (2003) NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis. J Cell Biochem 90(2):424–436. doi:10.1002/jcb.10625 CrossRefPubMed

36.

Morimoto R, Uehara S, Yatsushiro S, Juge N, Hua Z, Senoh S et al (2006) Secretion of L-glutamate from osteoclasts through transcytosis. EMBO J 25(18):4175–4186. doi:10.1038/sj.emboj.7601317 CrossRefPubMed

37.

Taylor AF (2002) Functional osteoblastic ionotropic glutamate receptors are a prerequisite for bone formation. J Musculoskelet Neuronal Interact 2(5):415–422PubMed

38.

Bhangu PS, Genever PG, Spencer GJ, Grewal TS, Skerry TM (2001) Evidence for targeted vesicular glutamate exocytosis in osteoblasts. Bone 29(1):16–23. doi:10.1016/S8756-3282(01)00482-3 CrossRefPubMed

39.

Bhangu PS (2003) ‘Pre-synaptic’ vesicular glutamate release mechanisms in osteoblasts. J Musculoskelet Neuronal Interact 3(1):17–29PubMed

40.

Genever PG, Skerry TM (2001) Regulation of spontaneous glutamate release activity in osteoblastic cells and its role in differentiation and survival: evidence for intrinsic glutamatergic signaling in bone. FASEB J 15(9):1586–1588PubMed

41.

Kalariti N, Lembessis P, Papageorgiou E, Pissimissis N, Koutsilieris M (2007) Regulation of the mGluR5, EAAT1 and GS expression by glucocorticoids in MG-63 osteoblast-like osteosarcoma cells. J Musculoskelet Neuronal Interact 7(2):113–118PubMed

42.

Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H (2007) Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 67(19):9463–9471. doi:10.1158/0008-5472.CAN-07-2034 CrossRefPubMed

43.

Wu Y, Shen D, Chen Z, Clayton S, Vadgama JV (2007) Taxol induced apoptosis regulates amino acid transport in breast cancer cells. Apoptosis 12(3):593–612. doi:10.1007/s10495-006-0007-y CrossRefPubMed

44.

Franklin RB, Zou J, Yu Z, Costello LC (2006) EAAC1 is expressed in rat and human prostate epithelial cells; functions as a high-affinity L-aspartate transporter; and is regulated by prolactin and testosterone. BMC Biochem 7:10. doi:10.1186/1471-2091-7-10 CrossRefPubMed

45.

Carrascosa JM, Martinez P, Nunez de Castro I (1984) Nitrogen movement between host and tumor in mice inoculated with Ehrlich ascitic tumor cells. Cancer Res 44(9):3831–3835PubMed

46.

Collins CL, Wasa M, Souba WW, Abcouwer SF (1998) Determinants of glutamine dependence and utilization by normal and tumor-derived breast cell lines. J Cell Physiol 176(1):166–178. doi:10.1002/(SICI)1097-4652(199807)176:1<166::AID-JCP18>3.0.CO;2-5 CrossRefPubMed

47.

Gonzalez-Cadavid NF, Ryndin I, Vernet D, Magee TR, Rajfer J (2000) Presence of NMDA receptor subunits in the male lower urogenital tract. J Androl 21(4):566–578PubMed

48.

Maxwell M, McCoy TA, Neuman RE (1956) The amino acid requirements of the Walker carcinosarcoma 256 in vitro. Cancer Res 16(10 Part 1):979–984PubMed

49.

Abdul M, Hoosein N (2005) N-methyl-D-aspartate receptor in human prostate cancer. J Membr Biol 205(3):125–128. doi:10.1007/s00232-005-0777-0 CrossRefPubMed

50.

Rzeski W, Turski L, Ikonomidou C (2001) Glutamate antagonists limit tumor growth. Proc Natl Acad Sci USA 98(11):6372–6377. doi:10.1073/pnas.091113598 CrossRefPubMed

51.

Rzeski W, Ikonomidou C, Turski L (2002) Glutamate antagonists limit tumor growth. Biochem Pharmacol 64(8):1195–1200. doi:10.1016/S0006-2952(02)01218-2 CrossRefPubMed

Title: Cancer cell lines release glutamate into the extracellular environment
Authors: Eric P. Seidlitz
Mohit K. Sharma
Zeina Saikali
Michelle Ghert
Gurmit Singh
Publication date: 01-10-2009
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 7/2009
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-009-9277-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2009

Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs

Expression and functional analysis of the WAP four disulfide core domain 1 gene in human melanoma

Functional blocking of specific integrins inhibit colonic cancer migration

Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation

Hepatocyte growth factor induced up-regulations of VEGF through Egr-1 in hepatocellular carcinoma cells

Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer